Home › Prostate Cancer › NCT01441089
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications
Who can join
Ages 3 and older · All sexes
Full eligibility criteria
* INCLUSION CRITERIA: * Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment. * Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document. * Age \>= 3 years old EXCLUSION CRITERIA: -N/A
About the study
Background:
\- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes.
Objectives:
\- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment.
Eligibility:
\- Individuals with cancer who are being treated at the National Cancer Institute.
Design:
* Participants will provide a blood sample for study. * Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample. * If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.
Sponsor: National Cancer Institute (NCI) · Participants: 1,100 · Started: May 21, 2012
Contact the study team
- Deneise C Francis, R.N. · Phone: (240) 858-3974
- William D Figg, Pharm.D. · Phone: (240) 760-6179
Official record on ClinicalTrials.gov — NCT01441089
Locations in the U.S.
| Maryland | National Institutes of Health Clinical Center, Bethesda |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.